Adaptive Biotechnologies Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00650F1093
USD
13.90
0.24 (1.76%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Adaptive Biotechnologies Corp.
Prime Medicine, Inc.
ADMA Biologics, Inc.
Inhibrx, Inc.
Dianthus Therapeutics, Inc.
Kymera Therapeutics, Inc.
Immatics NV
Cogent Biosciences, Inc.
Rayzebio, Inc.
Apogee Therapeutics, Inc.
Axcella Health, Inc.

Why is Adaptive Biotechnologies Corp. ?

1
With a growth in Net Sales of 13.44%, the company declared Outstanding results in Dec 25
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -48.04 MM
  • NET SALES(HY) At USD 165.65 MM has Grown at 76.43%
  • NET PROFIT(HY) Higher at USD -4.03 MM
2
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating Performance
  • The stock has generated a return of 62.62% in the last 1 year, much higher than market (S&P 500) returns of 16.12%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Adaptive Biotechnologies Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Adaptive Biotechnologies Corp. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Adaptive Biotechnologies Corp.
60.51%
4.03
72.28%
S&P 500
13.68%
0.84
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
23.00%
EBIT Growth (5y)
10.21%
EBIT to Interest (avg)
-88.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.53
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.37
EV to EBIT
-34.39
EV to EBITDA
-49.99
EV to Capital Employed
14.89
EV to Sales
7.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-43.29%
ROE (Latest)
-27.18%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -48.04 MM

NET SALES(HY)

At USD 165.65 MM has Grown at 76.43%

NET PROFIT(HY)

Higher at USD -4.03 MM

ROCE(HY)

Highest at -28.23%

RAW MATERIAL COST(Y)

Fallen by -30.23% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 8.89 times

DEBTORS TURNOVER RATIO(HY)

Highest at 5.93 times

-1What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 439.75 MM

Here's what is working for Adaptive Biotechnologies Corp.

Net Sales
At USD 165.65 MM has Grown at 76.43%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow
Highest at USD -48.04 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -4.03 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Profit
At USD -4.03 MM has Grown at 93.84%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Inventory Turnover Ratio
Highest at 8.89 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 5.93 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -30.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Adaptive Biotechnologies Corp.

Cash and Eqv
Lowest at USD 439.75 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents